DEF: Anteris Seeks Shareholder OK for ASX Waiver

Anteris Technologies Global Corp. is seeking stockholder approval for an ASX waiver to issue new securities without further shareholder consent, aiming for greater capital raising flexibility.

Summary

• A Special Meeting of Stockholders will be held virtually on September 4, 2025, at 5:00 p.m. Central time (8:00 a.m. AEST September 5, 2025).
• The primary purpose is to approve a waiver from ASX Listing Rule 7.1, which currently limits the company to issuing 15% of its fully-paid ordinary securities over a twelve-month period without stockholder approval.
• The waiver, if approved, would allow Anteris to issue new securities in excess of the 15% limit for a period of three years without additional stockholder approval under ASX rules, though Nasdaq listing rules would still apply.
• Stockholders will also vote on a proposal to adjourn the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes for the ASX Waiver Proposal.
• As of July 31, 2025, 36,062,370 shares of Common Stock (including CDIs) were outstanding and entitled to vote.
• The ASX Waiver Proposal requires an affirmative vote of 75% of votes cast on the matter.

Sentiment

Score: 5

Explanation: The filing presents a necessary procedural step for future financial flexibility, which is positive for long-term growth. However, it explicitly highlights the significant risk of dilution for existing shareholders, balancing the overall sentiment to neutral.

Positives

• The ASX waiver provides Anteris with additional flexibility in evaluating financing options and capital raising transactions.
• It aims to remove a significant disadvantage compared to other U.S. public companies not subject to the 15% limit under ASX Listing Rule 7.1.
• Increased capital raising flexibility is intended to help achieve the company's long-term goals, including completing the clinical development program and proposed commercialization of the DurAVR Transcatheter Heart Valve (THV) System.

Negatives

• Approval of the ASX Waiver Proposal carries a risk of economic and voting dilution for existing stockholders if the company issues equity securities in excess of the 15% limit.
• There is a risk that the market price for the company's Common Stock may be significantly lower on the date of any issuance than on the proxy statement date.
• Equity securities may be issued at a discount to the market price or as part of acquisition consideration, further impacting funds raised and dilution.

Risks

• Risk of economic and voting dilution for existing stockholders if equity securities are issued in excess of the 15% limit.
• Potential for the market price of Common Stock to be significantly lower at the time of issuance compared to the current date.
• Risk of issuing equity securities at a discount to market price or as acquisition consideration, impacting capital raised.
• The waiver could be revoked by ASX if the company fails to comply with conditions, Nasdaq listing rules change, or ASX policy settings change.

Future Outlook

The company anticipates needing additional funds to achieve its long-term goals, complete the clinical development program, and commercialize the DurAVR Transcatheter Heart Valve (THV) System. It aims to become and remain profitable by conducting clinical trials and seeking regulatory approvals for products like the DurAVR THV System.

Management Comments

• Our Board of Directors unanimously recommends that stockholders vote FOR the ASX Waiver Proposal.
• Our Board of Directors unanimously recommends that stockholders vote FOR the Adjournment Proposal.
• Wayne Paterson, Vice Chairman of the Board of Directors and Chief Executive Officer, signed the Notice of Special Meeting of Stockholders.

Industry Context

The company highlights that U.S. public companies not subject to ASX Listing Rules are able to offer and sell securities without the restrictions imposed by the 15% limit under ASX Listing Rule 7.1. This puts Anteris at a significant disadvantage in raising equity capital compared to its U.S. counterparts, especially given the capital-intensive nature of clinical development and commercialization in the medical device industry.

Comparison to Industry Standards

• The company explicitly states that it operates at a significant disadvantage in raising equity capital compared to other U.S. public companies due to the 15% limit under ASX Listing Rule 7.1.
• Alternative capital raising structures that are exceptions to ASX Listing Rule 7.1 are uncommon for U.S.-domiciled companies, further limiting Anteris's flexibility compared to its peers.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential economic and voting dilution if the company issues new equity securities in excess of the 15% limit, as explicitly detailed in the hypothetical dilution table.
• Management/Board: Gains increased flexibility in capital raising decisions, potentially enabling faster execution of financing strategies for product development and commercialization.

Next Steps

• Hold a Special Meeting of Stockholders on September 4, 2025, to vote on the ASX Waiver Proposal and the Adjournment Proposal.
• Announce preliminary voting results at the Special Meeting and release final results to the ASX and via a Current Report on Form 8-K within four business days after the meeting.
• Potentially undertake capital raising activities in the future, especially if the ASX waiver is approved, to fund clinical development and commercialization of the DurAVR THV System.

Key Dates

Recommendation

The filing is a procedural request for increased financial flexibility, which is generally positive for a company in clinical development. However, the explicit and significant risk of shareholder dilution from potential future capital raises, as detailed in the hypothetical scenarios, warrants caution. Investors should hold and monitor for actual capital raise announcements and their terms, as these will determine the true impact on share price and ownership.

Keywords

SEC filing, Proxy Statement, ASX Listing Rule 7.1, Capital Raise, Equity Dilution, Shareholder Approval, Corporate Governance, DurAVR THV System, Anteris Technologies Global Corp., Nasdaq Listing Rules